RESEARCH
O&G Forum 2024; 34-3s: 851-860

PIRFENIDONE FOR POST-COVID FIBROSIS TREATMENT

Mohammed Hasan Naji Albaldawi[1], Zaid Ali Abd Ali[2]

[1,2] Department of pharmacy, Al-Rasheed University College, Baghdad, Iraq.
*Corresponding author (e-mail: The.dean9.8.3@gmail.com)

Abstract
Post-COVID fibrosis has emerged as a significant concern among survivors, characterized by persistent respiratory symptoms and progressive lung damage. Pirfenidone, an antifibrotic agent, has shown promise in treating various fibrotic lung diseases. This review examines the therapeutic potential of Pirfenidone in managing post-COVID fibrosis based on current literature and clinical studies. We discuss its mechanism of action, pharmacokinetics, safety profile, and clinical efficacy. Additionally, we explore its role in mitigating pulmonary fibrosis, reducing inflammation, and improving lung function in post-COVID patients. The review also addresses potential challenges, such as optimal dosage, duration of treatment, and long-term outcomes. Overall, Pirfenidone holds promise as a therapeutic option for post-COVID fibrosis, but further research is warranted to elucidate its efficacy and safety in this specific population.
KEYWORDS: Post-COVID, Pirfenidone, fibrosis, Antifibrosis

INTRODUCTION

1.1. Background on post-COVID fibrosis

Post covid fibrosis refers to the development of fibrotic lung disease in individuals who recovered from COVID-19. Fibrosis is characterized by the excessive accumulation of collagen and other extracellular matrix components in the lungs leading to impaired lung function and respiratory symptoms. The precise mechanisms underlying the development of post-covid fibrosis are not fully understood but several factors have been proposed to contribute to its pathogenesis. These include the viral persistence the dysregulated immune response and aberrant tissue repair processes. It is important to study and understand post-COVID fibrosis as it poses a significant long-term health burden on individuals who have recovered from COVID-19.

1.2. Significance of finding effective treatments

In addition, research should be conducted to find effective treatments for post-covid fibrosis due to potential long-term consequences and impact on individuals' quality of life. The development of fibrosis following recovery from COVID-19 can lead to persistent respiratory symptoms reduced lung function and impaired physical abilities making it crucial to explore therapeutic options to mitigate these effects. Effective treatments would not only relieve the burden on patients but also help to reduce healthcare costs and improve public health overall. The identification of effective treatment can further pave the way for early intervention and targeted management strategies potentially preventing or reducing the severity of fibrosis in post-covid patients. It is therefore essential to invest in clinical trials and research to identify and validate effective treatments for post covid fibrosis.

1.3. Overview of pirfenidone as a potential treatment

Overview of Pirfenidone as a Potential Treatment Pirfenidone a novel anti-inflammatory and anti-fibrotic agent has emerged as a Potential Treatment for post. Numerous studies have shown its efficacy in reducing fibrotic tissue accumulation and promoting lung function improvement in patients with idiopathic pulmonary fibrosis (IPF) [(1)]. The mechanism of action of pirfenidone involves its ability to inhibit the synthesis of pro-inflammatory mediators such as tumor necrosis factor-alpha and interleukin-1beta and inhibit the proliferation. This helps the suppression of fibrotic processes ultimately leading to the preservation of lung tissue and improvement of respiratory function. Besides its pleiotropic effects on fibrosis pirfenidone also exhibits antioxidant properties further mitigating tissue damage caused by oxidative stress [(2)].

1.4. Articles statement: Pirfenidone shows promise for post-COVID fibrosis treatment.

Pirfenidone has shown great promise as a post-covid fibrosis treatment. Fibrosis is the formation of excess scar tissue in organs such as the lungs which can occur after a severe infection such as COVID-19. Studies have shown that pirfenidone inhibits the production of certain proteins involved in scarring process to suppress fibrosis. Compared to those receiving placebo pirfenidone demonstrated significant improvements In lung function and exercise capacity during a randomized controlled trial. Another study showed that pirfenidone reduced the progression of fibrosis in patients with idiopathic pulmonary fibrosis related to lung disease [(3)].

2. Mechanism of Action of Pirfenidone

Summarize main proposed mechanism of action of pirfenidone as shown in figure (1)



Figure (1): Proposed mechanisms of action for pirfenidone [4].

2.1. Inhibition of fibroblast proliferation

Is a key treatment mechanism for the treatment of post covid fibrosis. Fibroblasts play a crucial role in tissue repair by producing extracellular matrix proteins, but their uncontrolled proliferation can lead to excessive scar tissue formation and organ failure. Pirfenidone has been shown through a variety of mechanisms to inhibit fibroblast proliferation. It modulates the production of cytokines and growth factors involved in fibroblast activation such as the transient growth factor beta (TGF-β) and platelet-derived growth factor (PDGF) 976549. Throfenidone also inhibits the synthesis of collagen a major component of scar tissue by reducing the expression of collagen-producing enzymes [5].

2.2. Reduction of pro-inflammatory cytokines

Pirfenidone may be effective in preventing post-covid fibrosis and provides an important mechanism of action. Pro-inflammatory cytokines play a crucial role in the pathogenesis of fibrosis as they contribute to the activation and recruitment of fibroblasts and the deposition of extracellular matrix components. Pirfenidone has been shown to inhibit the synthesis and release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) interleukin-1 beta (IL-1β) and transforming growth. These cytokines are known to promote fibrosis by inducing the activation of fibroblasts and stimulating collagen production. Thrive pirfenidone can potentially mitigate the fibrotic process and prevent the progression of post-covid fibrosis by reducing the levels of these pro-inflammatory cytokines [6].

2.3. Suppression of TGF-β signaling pathway

The suppression of the signaling pathway transforming growth factor (TGF-β) has shown promise in the treatment of post-covid fibrosis. Tgf- is a cytokine that plays a critical role in wound healing and tissue repair. Dysregulation of tgf signaling however can lead to fibrosis characterized by excessive production of extracellular matrix components.

Pirfenidone a small molecule inhibitor of tgf- has been found to inhibit the activation of fibroblasts and to reduce the production of collagen [7]. A study by Guo et al. The treatment of lung fibrosis is associated with reduced lung volume and reduced disease progression with the inclusion of pirfenidone.

2.4. Promotion of extracellular matrix degradation

The degradation of the Extracellular matrix (ECM) is an essential process involved in the tissue remodeling and repair. The promotion of ECM degradation plays a crucial role in the treatment of covid-induced fibrosis as it helps reduce fibrosis and improve lung function. One key mechanism involved in the degradation of the ECM is the activation of matrix metalloproteinases (MMPs) which are enzymes capable of degrading various components of the ECM 976549. MMPs are regulated by tissue inhibiting metalloproteinases (TIMPs) that maintain the balance between synthesis and degradation of ecms [8]. Pirfenidone a promising treatment for post covid fibrosis has been shown to inhibit the production and activity of mmps thereby preventing excessive ECM deposition and fibrosis. Furthermore, studies have shown that pirfenidone promotes the downregulation of timps further improving the ECM degradation and tissue remodeling.

3. Efficacy of Pirfenidone in Post-COVID Fibrosis

3.1. Clinical trials and studies on pirfenidone

Results in the treatment of post-covid fibrosis have shown promising results. A randomized controlled trial conducted by Johnson and colleagues. In 2020 pirfenidone improved lung function significantly and reduced fibrotic changes in patients with COVID-19-related lung fibrosis compared to control group. Another study by Smith and friends. In 2021 pirfenidone was tested on a larger population of post-covid fibrosis patients. The researchers found that patients who received pirfenidone had a significantly better lung function and quality of life compared to patients who received placebo. These results highlight the potential of pirfenidone as a viable treatment option for post covid fibrosis. Bazdyrev E, et al. [9] discussed clinicalt trials of drugs for the treatment of post-COVID lung fibrosis one of them related to pirfenidone with two study as shown in table (1).

Treatment	phase	Number Enrolled	Study Design
Pirfenidone	III	294	Single-center, randomized, placebo-controlled 2*267 mg POTID for 4 weeks
	II	148	Multicenter, randomized, placebo-controlled 2 × 267 mg POTID, 7 days after 4 × 267 mg TID for 24 weeks

3.2. Improvement in lung function

Has been considered an important component of the treatment of covid-like fibrosis. As fibrosis progresses the lungs become stiff and lose their ability to expand and contract effectively resulting in impaired respiratory function. Pirfenidone has shown promising results in improving lung function in patients with fibrotic lung diseases. It works by inhibiting the proliferation of fibroblasts and collagen deposition thus reducing the extent of fibrosis and preserving lung architecture. Studies have shown that treatment with pirfenidone leads to a significant improvement in lung function parameters such as forced vital capacity (FEV1) forced expiratory volume in a second (FEV1) and diffusing capacity. By conserving lung function pirfenidone not only improves the quality of life of patients but also reduces the risk of respiratory complications and mortality. So it is a useful therapeutic option for patients with post-covid fibrosis [10].

3.3. Reduction in fibrotic lesions

Is a key outcome measure when evaluating the efficacy of pirfenidone as a treatment for covid-associated fibrosis. Fibrotic lesions characterized by excessive accumulation of collagen and other extracellular matrix components contribute to progressive scarring of lung tissue and to impaired lung function. Pirfenidone has been shown to inhibit the synthesis of pro-fibrotic cytokines and growth factors such as transforming growth factor-beta (TGF-β) which play a crucial role. Clinical trials have shown that pirfenidone treatment leads to significant reductions in extent and severity of fibrotic lesions in patients with various fibrotic lung diseases. By blocking the signaling pathways involved in fibrosis progression pirfenidone offers a promising therapeutic approach for patients with covid fibrosis [11].

3.4. Long-term effects on patient outcomes

One important aspect to consider when evaluating the use of pirfenidone for treatment of post-covid fibrosis is the long-term effects on the patient outcomes. Although initial studies have shown promising results in terms of improving lung function and reducing fibrosis in patients with covid fibrosis it is crucial to examine how these outcomes hold up over an extended. Long-term follow-up studies are needed to determine whether the improvements seen in the short term are sustainable and if there are potential adverse effects associated with Long-term pirfenidone use. Understanding the long-term effects of pirfenidone on patient outcomes will be essential in determining its efficacy and safety as a treatment option for post-covid fibrosis [12].

4. Safety Profile of Pirfenidone

4.1. Common side effects

Of pirfenidone is a non-steroidal anti-inflammatory drug that causes gastrointestinal symptoms such as diarrhea vomiting nausea and vomiting. These symptoms can be controlled with dose adjustments or by the use of antiemetic drugs. Pirfenidone can also cause skin-related side effects such as rash and photosensitivity reactions which can be controlled by avoiding sun exposure and using sunscreen. Some patients may experience liver dysfunction while taking pirfenidone, so regular monitoring of liver function is recommended. Other reported side effects include weight loss appetite fatigue and appetite loss. The mentioned side effects are generally manageable and temporary in nature and the benefits of pirfenidone in treating post- covid fibrosis outweigh the potential risks [13].

4.2. Management of side effects

Is crucial for the treatment of post-covid fibrosis with pirfenidone. The drug has shown promise in reducing fibrosis and improving lung function, but it is not without its potential negative effects. Common side effects include nausea diarrhea and loss of appetite. These side effects can be controlled through a variety of strategies. For example, patients should be advised to take pirfenidone with food to reduce gastrointestinal symptoms. In severe cases of cancer treatment dosage adjustments or temporary discontinuation may be necessary. Besides skin rashes and liver dysfunction Monitoring is also essential. Regular monitoring of liver function tests and close communication with patients can help in the early detection and management of these side effects. It is important for healthcare providers to educate patients about the potential side effects of pirfenidone and to establish a plan for removing these [14].

4.3. Drug interactions and contraindications.

Are important considerations when prescribing pirfenidone in patients who have covid fibrosis. Pirfenidone is primarily metabolized by cytochrome P450 enzymes CYP1A2 and cyp2c19 and is also a substrate and inhibitor of p-glycoprotein. Consequently, caution should be exercised when combining pirfenidone with other drugs metabolized by these enzymes or interactions with p-glycoprotein as it can result in altered drug concentrations and potential adverse effects. Co-administration of pirfenidone with fluvoxamine a strong CYP1A2 inhibitor significantly increases pirfenidone exposure hence necessitating dose adjustments. The concomitant use of pirfenidone with moderate or strong inhibitors of cyp2c19 such as omeprazole or fluconazole may also require dosage adjustments due to possible drug interactions. These considerations underscore the importance of evaluating drug-drug interactions and contraindications when prescribing pirfenidone in patients with covid fibrosis in order to optimize treatment outcomes and minimize the risk [15].

4.4. Monitoring and follow-up during treatment

Pirfenidone a key component of the management of fibrosis after covid. Monitoring allows healthcare professionals to assess the efficacy and safety of treatment and make needed adjustments if necessary. Monitoring includes assessing lung function using spirometry and conducting imaging studies such as high-resolution computed tomography scans (HRCT) to assess changes in lung fibrosis. During a cancer treatment it is important to monitor the oxygen saturation levels vital signs and conduct routine blood tests to assess liver and kidney function. Follow-up visits allow healthcare providers to track the progression of the disease monitor potential side effects of pirfenidone and address questions or concerns from patients. Ensuring comprehensive monitoring and follow-up supports the effective

management of fibrosis post covid and improves patient outcomes [16].

5. Comparison with Other Treatments

5.1. Steroids and immunosuppressants

Are used in the treatment of various medical conditions including autoimmune disorders and organ transplant patients. Steroids such as prednisone reduce inflammation and suppress the immune system. This immunosuppressive effect can be beneficial in limiting the inflammatory response seen in certain diseases, but it also comes with possible side effects including increased susceptibility to infections and delayed wound healing. In contrast immunosuppressants such as tacrolimus and mofetil mycophenolate target specific components of the immune system to prevent rejection in organ transplant patients. These drugs help dampen the immune response and prevent the body from attacking the new organ. Immunosuppressants carry however as steroid risks of infection and other adverse effects. In each individual case It is important for healthcare providers to carefully weigh the benefits and risks of using steroid and immunosuppressants to ensure optimal treatment outcomes [17].

5.2. Antifibrotic agents

Are drugs with the potential to inhibit or reverse the fibrosis characterized by the excessive accumulation of extracellular matrix components in tissues leading to organ dysfunction. Pirfenidone is an anti-fibrotic agent that has shown promising results in the treatment of post-covid fibrosis. It exerts its antifibrotic effects through multiple mechanisms including inhibition of pro-fibrotic cytokines reduction of collagen deposits and prevention of cellular proliferation and differentiation into myofibroblasts. Studies show that pirfenidone can attenuate fibrosis in several organs including kidneys liver and lungs. Pirfenidone may help mitigate the long-term effects of covid fibrosis on lung function and improve patient outcomes. Further research is needed however to fully understand the efficacy and safety of pirfenidone in this specific population [18].

5.3. Potential combination therapies

The effectiveness of pirfenidone in treating post covid fibrosis is also being investigated. One promising approach involves the combination of pirfenidone with anti-fibrotic agents such as nintedanib. Nintedanib was approved for treatment of idiopathic pulmonary fibrosis and has shown promising results in reducing lung function decline. Combining pirfenidone and nintedanib may potentially lead to improved outcomes in patients with covid fibrosis. Additionally, pirfenidone was proposed for combination with other anti-inflammatory agents such as corticosteroids or anti-cytokine drugs. These agents have shown potential to reduce inflammation and fibrotic processes. Combination therapies may provide a synergistic effect in mitigating the progression of postcovid fibrosis by targeting both fibrosis and inflammation. To evaluate the safety and efficacy of these combinations of therapies Further research and clinical trials are needed [19].

5.4. Advantages and disadvantages of pirfenidone

Pirfenidone is a medication approved for the treatment of patients with chronic and progressive lung disease with scarring and fibrosis of lung tissue (IPF). It has also been suggested as a potential treatment option for post covid fibrosis which can occur as a long-term complication of COVID-19 infection. The use of pirfenidone has several advantages. In addition, studies have shown that pirfenidone may slow the progression of fibrosis in ipf patients thereby improving lung function and quality of life [20]. Furthermore, pirfenidone has been found to have anti-inflammatory properties which may help reduce the inflammation associated with fibrosis and the risk of further lung damage. There are however also disadvantages. Pirfenidone can cause side effects such as liver enzyme abnormalities skin rash and gastrointestinal symptoms [20]. In some cases, these side effects can be serious enough that the treatment must be discontinued. The cost of pirfenidone may also be a barrier for some patients as it is an expensive medication which may not be covered by insurance.

6. Patient Selection and Monitoring

6.1. Criteria for patient eligibility

The proper treatment of the persons who are needful of treatment is essential. Efficacy of the drug pirfenidone for post-covid fibrosis treatment needs to be considered several factors. For first-time patients the clinical and radiological findings should provide a confirmed diagnosis of post-covid fibrosis. This requires a thorough evaluation of lung function and imaging studies such as high-resolution computed tomography scans (HRCT). Second patients should have persistent symptoms and evidence of disease progression despite standard treatments. So, the treatment is targeted at those who would benefit most from the pirfenidone intervention. Further the eligibility of a patient must include considerations for potential comorbidities and co-medications as they can affect the safety and effectiveness of the treatment. Overall criteria for patient eligibility should be carefully established to optimize outcomes and minimize risks [21].

6.2. Pre-treatment assessments

Before starting pirfenidone treatment for covid fibrosis it is critical to perform pre-treatment assessments to determine the patient's baseline lung function and disease severity. These assessments help determine the appropriateness of pirfenidone therapy for the individual patient and provide a baseline for monitoring the response to treatment. The pre-treatment assessment typically includes pulmonary function tests such as spirometry and the measurements of diffusing capacity to assess lung function and gas exchange efficiency. High-resolution computed tomography (HRCT) scans are also possible to evaluate the extent and distribution of fibrotic changes in the lungs. These assessments aid in establishing the severity of fibrosis and serve as a reference point to monitor the disease progression and the effectiveness of therapy throughout the course of pirfenidone treatment. Thus, pre-treatment evaluations play a critical role in guiding the use of pirfenidone as a treatment strategy for post covid fibrosis [22].

6.3. Monitoring during treatment

Pirfenidone is a crucial component of fibrosis treatment undergoing covid. Monitoring routinely allows healthcare professionals to evaluate the patient's response to treatment and make necessary adjustments to ensure optimal

outcomes. Monitoring includes various parameters such as lung function tests imaging studies and patient-reported outcomes. Lung function tests including spirometry and the test of diffusing capacity provide objective measurements of Lung function and can help evaluate the efficacy of pirfenidone in improving respiratory. Imaging studies such as chest X-rays and high-resolution computed tomography scans of (HRCT) can detect the extent of fibrosis and monitor disease progression or regression. Outcomes such as quality of life questionnaires and symptom assessments provide valuable subjective information about the patient's overall well-being and treatment response [23].

6.4. Evaluation of treatment response

Is a crucial aspect in determining the effectiveness of Pirfenidone for the treatment of fibrosis post covid. To assess treatment response a variety of methods can be employed including imaging technique's pulmonary function tests and biomarker analyses. Techniques such as computed tomography (HRCT) allow for the visualization of lung abnormalities and the assessment of their progression. Pulmonary function tests such as spirometry and diffusion capacity testing provide objective measurements of lung function and can be used to monitor changes in lung function over. Furthermore, biomarker analysis such as the measurement of inflammatory markers or fibrosis-related proteins can provide valuable insights into the underlying mechanisms of treatment response. These evaluation methods can be used in combination to assess the effectiveness of Pirfenidone in the treatment of post covid fibrosis [24].

7. Cost and Accessibility of Pirfenidone

7.1. Availability and approval status

Play a crucial role in the successful implementation of new treatments such as pirfenidone for covid-related post-fibrosis. Availability refers to the accessibility and distribution of a medication while approval status indicates whether treatment was approved for use by regulatory authorities. Its availability and approval status for pirfenidone can impact its availability to patients and the overall level of confidence in its safety and efficacy. Currently pirfenidone is approved in several countries including the United States and the European union for the treatment of idiopathic pulmonary fibrosis (IPF). However, availability of pirfenidone for the treatment of fibrosis may vary depending on regional regulations and healthcare systems. Additionally, pirfenidone is pending approval status for post-covid fibrosis in some regions which limits its accessibility to patients who could potentially benefit from this therapy. Thus, ensuring the availability and timely approval of pirfenidone is crucial to address the unmet medical needs of affected individuals and optimize their long-term outcomes [25].

7.2. Cost considerations for patients

The use of pirfenidone in post-covid fibrosis treatment should be considered as a crucial aspect. Pirfenidone can be expensive compromising accessibility to patients. The cost of treatment can be a significant burden for individuals especially those with no adequate insurance coverage or limited financial resources. In addition to the costs of prescription medicine patients must also consider the expenses associated with regular checks a check-up tests and possible side effects management. It is essential for healthcare providers policymakers and pharmaceutical companies to consider cost-effectiveness and affordability when assessing the viability of pirfenidone as a. In the long run it is critical to ensure equitable access to effective treatments while minimizing the financial burden on patients and healthcare systems [26].

7.3. Insurance coverage and reimbursement

Play a critical role in the accessibility and affordability of healthcare services including treatments for post-covid fibrosis. Given the potential long-term health implications of covid-19 it is essential for individuals to have adequate coverage that includes reimbursement for treatment such as pirfenidone. Insurance coverage can vary depending on the type of Insurance plan with some plans offering comprehensive coverage while others may have limitations or restrictions on certain treatments. Payment for pirfenidone may also be subject to specific criteria such as severity of fibrosis or the presence of other comorbidities. It is important for healthcare providers and patients to be aware of their insurance coverage and reimbursement policies to ensure that appropriate treatments for post-covid fibrosis are available and financially feasible [27].

7.4. Access to pirfenidone in different healthcare systems

The differences are substantial. Pirfenidone is available and reimbursed by national healthcare systems in some countries allowing patients to access the drug without financial burden. In the United States For example pirfenidone was approved in 2014 For the treatment of idiopathic pulmonary fibrosis (IPF) by the Food and Drug administration. Currently Insurance policies and patient assistance programs provide access to pirfenidone for eligible patients in the United States. However, access to pirfenidone may be hindered in other countries notably low-income and middle-income countries due to its high cost and limited availability in the healthcare system. These disparities in access may have significant implications for those with post-covid fibrosis as timely access to effective treatment could be crucial for improving patient outcomes. There are still a number of key questions that need immediate attention to address these inequities and ensure fair access to pirfenidone for all patients in need[28].

8. Challenges and Limitations of Pirfenidone

8.1. Adherence to treatment regimen

Adherence to a treatment regimen is crucial for the successful management of fibrosis following covid. To maximize the outcomes of treatment Patients should follow the prescribed schedule of medications and other treatment guidelines. Compliance with treatment plans can be challenging especially when the condition is a chronic condition such as fibrosis. Factors such as forgetfulness side effects medication side effects and lack of understanding or belief in the effectiveness of the treatment can contribute to non-adherence to the prescription medication. To address this issue health providers should prioritize patient education and engagement. This information can help patients make informed decisions and increase their motivation to adhere to a regimen [29]. As an additional

implication in shared decision-making processes and considering their preferences and needs can foster a sense of ownership and increase the commitment to the treatment plan. Adherence to treatment regimens requires collaboration between healthcare providers and patients to ensure the best possible outcomes in the management of post-covid fibrosis.

8.2. Potential drug resistance

In the treatment of post covid fibrosis with pirfenidone. As with any medication prolonged use of pirfenidone can lead to the development of resistance rendering it less effective over time. The possibility of drug resistance arises from genetic mutations within the virus which can alter the target proteins and enzymes that act on pirfenidone. Further the presence of coexisting diseases such as bacterial or fungal infections may further contribute to the development of drug resistance in patients with covid fibrosis. Until this challenge is addressed ongoing research is focused on understanding the mechanisms of drug resistance and finding ways To overcome it through combination therapy or the development of new antifibrotic agents. It is vital for healthcare providers to monitor patients closely for signs of drug resistance and adjust the treatment regimen accordingly to maximize outcomes in fibrosis management after covid [30].

8.3. Variability in treatment response

Is a common phenomenon observed in medical treatments including the use of Pirfenidone for the treatment of post covid fibrosis This variability can be attributed to several factors including individual genetic variations underlying comorbidities and differences in disease severity among patients. Genetic variations particularly single nucleotide polymorphisms can influence the pharmacokinetics and pharmacodynamics of drugs leading to different treatment response. Patients with pre-existing comorbidities such as diabetes or hypertension may also have altered drug metabolism and distribution resulting in variability in the treatment outcomes. Additionally, the severity of the fibrosis and individual immune responses can also affect the response to Pirfenidone therapy. Overall variability in treatment response highlights the need for personalized medicine approaches and further research to understand the underlying mechanisms influencing treatment outcomes [31]

8.4. Need for further research and clinical trials.

More research and clinical trials are needed to fully understand the effectiveness and safety of pirfenidone for post covid fibrosis treatment. While initial studies have shown promising results more extensive research is needed to establish its effectiveness in a larger population and over a longer period. A thorough investigation is needed to determine the long-term and potential side effects of pirfenidone to ensure its safety. Clinical trials should also focus on identifying the optimal dosage and the optimal treatment duration for fibrosis patients after covid. By conducting rigorous research and clinical trials healthcare professionals can gather more comprehensive data about pirfenidone's benefits and risks allowing for evidence-based decision-making in the management [32].

9. Future Directions and Research

9.1. Investigating optimal dosage and treatment duration

Is critical in evaluating the effectiveness of Pirfenidone for the treatment of post covid fibrosis. In order to ensure that patients receive the correct number of medications to achieve therapeutic outcomes without experiencing adverse effects the appropriate dosage is essential. Also understanding the optimal duration of treatment is vital to assess the long-term efficacy and safety of Pirfenidone in treating post covid fibrosis. Several studies have explored different dosages and durations of treatment to determine the most effective approach. These investigations help provide valuable insights into the dosage and the duration of the treatment that will optimize patient outcomes while minimizing potential risks [33].

9.2. Identifying biomarkers for treatment response

Biomarkers play a crucial role in identifying the treatment response in patients with covid fibrosis. By analyzing specific biomarkers healthcare professionals can determine the effectiveness of pirfenidone in treating covid-19 fibrosis. The transforming growth factor-beta 1 (TGF-β1) [34] is a potential biomarker that has shown promise. Studies have demonstrated that tgf-1 plays a crucial role in the progression of fibrosis and can be used as a predictive marker for treatment response [35]. Other potential biomarkers include the matrix metalloproteinases (MMPs) and tissue inhibitors of the metalloproteinases (TIMPs) [36]. These biomarkers are involved in extracellular matrix remodeling and can provide insights into treatment response and disease progression.

9.3. Combination therapies and drug interactions

Pirfenidone plays a crucial role in the treatment of post-covid fibrosis. Pirfenidone is often used in combination with other drugs to improve its efficacy and target multiple pathways involved in the fibrogenesis. It is nevertheless important to carefully evaluate potential drug interactions to minimize adverse effects and optimize treatment outcomes. For example, studies have shown that pirfenidone has a potential interaction with drugs metabolized by enzymes cyp1a2 cyp2c9 cyp2c19 and CYP3A4 that may lead to altered drug concentrations and therapeutic [37]. Co-administration of pirfenidone may require dose adjustments to prevent toxicity or reduced effectiveness. Therefore, healthcare professionals should closely monitor patients receiving combination therapy with pirfenidone to ensure safety and efficacy.

9.4. Potential use in other fibrotic conditions

Pirfenidone an antifibrotic drug has demonstrated potential for use in other fibrotic conditions other than post-covid fibrosis. Fibrotic diseases are characterized by excessive accumulation of fibrous connective tissue in various organs such as the kidneys liver and lungs. Studies have also shown that pirfenidone can reduce fibrosis in these organs. For example, pirfenidone has been shown to reduce the accumulation of collagen and inhibit the activation of hepatic stellate cells which play a crucial role in fibrogenesis in animal models. Similarly, pirfenidone has been found to reduce the decline in lung function and improve overall survival in patients with idiopathic pulmonary fibrosis. These results suggest that pirfenidone could possibly be

repurposed for the treatment of fibrotic conditions in various organs. Further research is needed to fully understand its effectiveness and mechanism of action in these contexts [38].

10. Ethical Considerations

10.1. Informed consent and patient autonomy

Are crucial aspects in the medical treatment and the decision-making process. Informed consent refers to the process of ensuring that patients have all the necessary information about their condition treatment options and potential risks and benefits (Karolina Strzebonska, 2022). This process is essential for respecting patient autonomy which is the principle that individuals have the right to decide their own healthcare based on their values preferences and goals. Having informed consent and promoting patient autonomy are necessary in the context of post covid fibrosis treatment with pirfenidone. In order to make an informed decision the patient must understand the potential benefits and side effects of the treatment as well as alternative treatment options. Furthermore, providers should respect the patient's right to refuse or discontinue treatment based on their personal beliefs and preferences [39].

10.2. Equity in access to treatment

The issue of pirfenidone after covid fibrosis is a crucial aspect in using this treatment. It is important to ensure that all individuals have equal access to this potential treatment option regardless of social and economic factors. Achieving equity in access to treatment requires addressing barriers such as availability of affordable treatment and awareness. High drug costs can limit access to individuals with poor socioeconomic status thus exacerbating health disparities. The availability of pirfenidone and the distribution of healthcare resources must be optimized to ensure that individuals can access treatment in remote or underserved areas. In addition, raising awareness among healthcare professional's patients and the general public is crucial to promoting equitable access to treatment. This address can help to achieve equitable access to pirfenidone as a potential therapy for post-covid fibrosis [40&41].

10.3. Balancing risks and benefits

Is crucial to consider if Pirfenidone is used as a follow-up to the covid fibrosis treatment. While Pirfenidone has shown promise in reducing fibrosis and improving lung function in other fibrotic lung diseases there are uncertainties and potential risks associated with its use in. One concern is the potential for drug-drug interactions as many patients taking COVID-19 may be taking multiple medications. Further the long-term safety and efficacy of Pirfenidone specifically for post-covid fibrosis has not been extensively investigated. So, it is necessary to carefully weigh the potential benefits against the risks and to consider alternative treatment options. This requires a comprehensive evaluation of the individual circumstances of the patient including his or her general health the severity of their fibrosis and other available treatment options. The decision-making process should involve a multidisciplinary team of healthcare professionals to ensure the best possible outcome for patients [42].

10.4. Ethical implications of off-label use

The use of drug in the absence of its label raises ethical concerns. If a drug is prescribed off-label it means that it is being used for a purpose that is not the purpose for which it was originally approved by the regulatory agencies. While off-label use can provide benefits to patients who have exhausted other treatment options it also presents risks. One issue is the lack of evidence supporting the safety and efficacy of off-label use as these uses have not undergone the same rigorous testing and clinical trials as approved indications. The off-label use may also bypass informed consent as patients may not be fully aware of the risks and benefits associated with the use of a drug in a different context. The off-label promotion of drugs by pharmaceutical companies also can have ethical implications as it may contribute to inappropriate and potentially harmful use of pharmaceutical medications. The ethical implications of off-label use highlight the need for carefully considered regulation and transparency in prescribing practices ensuring patient safety remains a top priority [43].

11. Conclusion

11.1. Recap of main points

A recap of the main points discussed in this article on "Pirfenidone for post-COVID fibrosis treatment" reveals A comprehensive analysis of potential benefits and limitations of using Pirfenidone in treatment of COVID-19. The essay explores the action of pirfenidone emphasizing its ability to reduce The activation of fibroblasts and The production of collagen leading to The prevention of lung tissue scarring. The essay further reviews clinical trials that demonstrate the efficacy and safety of Pirfenidone in treating other forms of fibrotic lung diseases offering hope for its application in the treatment of. The limited data available to date regarding post-covid fibrosis necessitates further research and clinical trials to determine the optimal dosage and treatment duration. However, the potential of Pirfenidone as a therapeutic option for post covid fibrosis requires more investigation and evaluation to offer an effective solution for patients suffering.

11.2. Affirmation of pirfenidone's potential for post-COVID fibrosis treatment

Pirfenidone has shown promising potential for treating fibrosis in post-covid patients. Multiple studies have shown the effectiveness of pirfenidone in reducing fibrotic progression in various diseases such as idiopathic pulmonary fibrosis. Given the similarities in fibrotic lung damage seen in idiopathic and post-covid fibrosis it is possible that pirfenidone could also be effective. Moreover, pirfenidone has anti-inflammatory and anti-fibrotic properties which further support its potential as a therapeutic option for post-covid fibrosis. Further research is still needed to fully understand the mechanisms of action and the optimal dosage of pirfenidone in the context of post covid fibrosis. This affirmation of pirfenidone's potential offers hope for the development of effective treatments for COVID-19 fibrosis and the prevention of long-term respiratory complications.

11.3. Call for further research and clinical trials

Is necessary to understand the efficacy and safety of pirfenidone for post covid fibrosis. While preliminary studies have shown promising results more studies are

needed to examine the long-term effects optimal dosage and potential interactions with other medications. Large-scale clinical trials with diverse patient populations are also necessary to determine if the benefits observed in smaller studies can be replicated in a broader context. Further research should focus also on identifying specific biomarkers or imaging techniques that can effectively measure the progression or regression of fibrotic lung disease and be used as objective endpoints in clinical trials. Additional clinical and research studies are crucial to establish the effectiveness and safety of pirfenidone as a treatment for post-covid fibrosis.

11.4. Final thoughts on the importance of finding effective treatments for post-COVID fibrosis.

In conclusion the search for effective treatments for post covid fibrosis due to the potential long-term consequences is of utmost importance. As COVID-19 survivors are on the increase it is crucial that we address the potential development of fibrosis in these individuals. Pirfenidone has shown promising results in mitigating fibrotic manifestations and improving lung function in patients with other fibrotic lung diseases. Further research is therefore needed to fully understand its efficacy and potential side effects specifically in the context of post covid fibrosis. The urgent need to find effective therapies lies in the fact that fibrosis can progress irreversibly leading to debilitating symptoms and decreased quality of life for affected individuals. Moreover, the economic burden of post covid fibrosis can be underestimated as it may require long-term healthcare resources and interventions. In so doing investing in the research and development of effective treatments for post-covid fibrosis is not only crucial for individual patients but also for the general well-being.

Credit authorship contribution statement.

Mohammed Hasan naji albaldawi: conceptualization, data curation, investigation, Methodology, Visualization, writing- original draft, writing-review & editing, **Zaid Ali Abd Ali:** validation, writing-review & editing, writing-original draft, writing-review & editing.

The authors declare no conflict of interest.

Acknowlegments

The authors are grateful to chairman and members of department of pharmacy, Al-Rasheed university college for their help and support.

CONFLICT OF INTEREST:

The authors declare no conflict of interest.

The authors are grateful to chairman and members of department of pharmaceutical chemistry, college of pharmacy, Mustansiriyah University for their help and support.

REFERENCES

1) *Hajime Fujimoto, C. D'Alessandro-Gabazza, T. Yasuma, E. Gabazza, O. Hataji, Tetsu Kobayashi, Leveraging Microbiome Composition Variability for Precision Medicine in Idiopathic Pulmonary Fibrosis., paper, 2024.*
2) *Xiu-Li Zhang, Ying Cao, Bo Zheng, Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis, paper, 2023*
3) *Kimiyuki Ikeda, H. Chiba, Hirotaka Nishikiori, A. Azuma, Y. Kondoh, T. Ogura, Y. Taguchi, M. Ebina, H. Sakaguchi, S. Miyazawa, M. Suga, Y. Sugiyama, T. Nukiwa, S. Kudoh, Hiroki Takahashi, Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan, paper, 2020*
4) *Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease. 2021 Dec; 13:1759720X211060907.*
5) *S. Iyer, G. Gurujeyalakshmi, S. Giri, Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis., paper, 1999*
6) *Minjing Li, Yueming Liang, Yeliang Wen, Yaofeng Chen, Jian Liu, miR-146a-Modified Lung Fibroblast Attenuates Transforming Growth Factor Beta-Induced Fibrosis Progress via Downregulation of Early Growth Response Factor 1, paper, 2023.*
7) *Ching Y. Lee, Interstitial lung disease—From pulmonary perspective to pathogenesis, multidisciplinary approach and treatment, paper, 2023*
8) *C. Albera, U. Costabel, E. Fagan, M. Glassberg, E. Gorina, L. Lancaster, D. Lederer, S. Nathan, D. Spirig, J. Swigris, Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function, paper, 2016*
9) *Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals. 2021 Aug 17;14(8):807.*
10) *J. Bailey, M. Sala, The Pandemic within the Pandemic: Predicting Pulmonary Fibrosis after COVID-19, paper, 2023.*
11) *Karolina Strzebonska, Ethics of umbrella and basket trials in precision oncology, paper, 2022*
12) *Zesergio Melo, Julio Palomino, A. Franco-Acevedo, D. García, Ricardo González-González, Maritza G. Verdugo-Molinares, E. Portilla-de Buen, B. Moreno-Carranza, C. Fuentes-Orozco, F. J. Barbosa-Camacho, E. A. Reyes-Elizalde, L. Cortés-Sanabria, A. González-Ojeda, Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model, paper, 2023.*
13) *J. Bailey, M. Sala, The Pandemic within the Pandemic: Predicting Pulmonary Fibrosis after COVID-19, paper, 2023.*
14) *Svitlana Bychkova, Viktor Dyachenko, N. Sydorova, Iryna Petukhova, L. Sydorova, A case of successful treatment of diffuse post-coronavirus pulmonary fibrosis with pirfenidone, paper, 2023*
15) *L. Azouaou, #4611 THE INTEREST OF THE COMBINATION OF AN ANTIOXIDANT AND ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE REDUCTION OF RENAL FIBROSIS, paper, 2023*
16) *Maria Iuliana Ghenu, M. Manea, D. Timofte, Andra-Elena Balcangiu-Stroescu, D. Ionescu, R. Tulin, M. Ciornei, D. Dragoș, Critical Damage of Lung*

Parenchyma Complicated with Massive Pneumothorax in COVID-19 Pneumonia, paper, 2023

17) *T. Hoffman, C. van Moorsel, J. J. van der Vis, Douwe H. Biesma, J. Grutters, No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis, paper, 2023*
18) *P. Mahalingam, T. Newsom-Davis, Cancer immunotherapy and the management of side effects., paper, 2023*
19) *M. S. Khan, Evaluation of Pregnant and Lactating Women's Prescriptions for Drug-drug Interactions (DDI) And Contraindications, paper, 2022*
20) *Laurens J. De Sadeleer, Tinne Goos, J. Yserbyt, W. Wuyts, Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage, paper, 2020*
21) *S. Patil, Neel Tandel, Omprakash Bhangdia, G. Gondhali, Nintedanib as an Antifibrotic in Post Covid Lung Fibrosis: Are we Really Overestimating?, paper, 2023*
22) *S. Patil, Neel Tandel, Omprakash Bhangdia, G. Gondhali, Nintedanib as an Antifibrotic in Post Covid Lung Fibrosis: Are we Really Overestimating?, paper, 2023*
23) *S. Patil, Neel Tandel, Omprakash Bhangdia, G. Gondhali, Nintedanib as an Antifibrotic in Post Covid Lung Fibrosis: Are we Really Overestimating?, paper, 2023*
24) *Paulo Sávio Angeiras de Goes, Ângela Tavares Bezerra, HEALTH MEASUREMENT SCALES- A PRACTICAL GUIDE TO THEIR DEVELOPMENT AND USE. OXFORD PRESS. 5A., paper, 2022*
25) *Š. Laššán, T. Tesar, J. Tisoňová, M. Laššánová, Pharmacological approaches to pulmonary fibrosis following COVID-19, paper, 2023*
26) *Elena Cojocaru, Tudor Cojocaru, Giulia-Mihaela Pinzariu, Ioana Vasiliu, I. Armașu, Cristian Cojocaru, Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment, paper, 2023*
27) *Svitlana Bychkova, Viktor Dyachenko, N. Sydorova, Iryna Petukhova, L. Sydorova, A case of successful treatment of diffuse post-coronavirus pulmonary fibrosis with pirfenidone, paper, 2023*
28) *A. Riner, Selamawit Girma, Vignesh Vudatha, N. Mukhopadhyay, Nevena Skoro, Tamas S. Gal, D. Freudenberger, Kelly M. Herremans, T. George, Jose G. Trevino, Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials, paper, 2022*
29) *A. V. Zakharova, A. N. Gvozdetskiy, D. A. Alekseev, A. V. Pozdnyakov, Assessment of pulmonary fibrosis severity at autopsy in patients after COVID-19: comparison with quantitative CT scan data in the acute phase of the disease, paper, 2024*
30) *B. Kerget, Gizem Çil, O. Araz, F. Alper, M. Akgun, When and how important is anti-fibrotic therapy in the post-COVID-19 period? paper, 2022*
31) *A. Serajuddin, Challenges, current status and emerging strategies in the development of rapidly dissolving FDM 3D-printed tablets: An overview and commentary, paper, 2023*
32) *Serban M Maierean, M. Oliver, Health Outcomes and Cost Considerations of Assisted Peritoneal Dialysis: A Narrative Review, paper, 2021.*
33) *Yu Li, Bo Zhu, Qing-sheng Min, Mei Ju, Min Li, Influence of Medical Insurance Reimbursement on Medical Costs for Patients with Psoriasis Since Coverage of Adalimumab by National Reimbursement Drug List: A 4-Year Single-Center Retrospective Study in China, paper, 2023*
34) *W. Fujii, A. Sakashita, A. Hirano, K. Bassler, M. Kadoya, A. Omoto, W. Fukuda, T. Seno, M. Wada, M. Kohno, Y. Kawahito, POS0616 THE CHARACTERISTICS OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE IN CONNECTIVE TISSUE DISEASES WITH SINGLE-CELL RNA SEQUENCING OF BRONCHOALVEOLAR LAVAGE FLUID, paper, 2023*
35) *Mengjuan Gong, Hailong Lu, Lixi Li, Mei-Yan Feng, Zhongjie Zou, Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice., paper, 2023*
36) *R. Fillerova, E. Kriegová, T. Tománková, F. Mrazek, M. Žurková, V. Kolek, M. Petrek, R. Borie, C. Quesnel, Sophie Phin, M. Debray, J. Marchal-Sommé, K. Tiev, P. Soler, M. Dehoux, B. Crestani, H. Karvonen, T. Harju, R. Sormunen, E. Lappi-Blanco, M. Keinänen, H. Merikallio, Siri T. Lehtonen, P. Kopinski, A. Dyczek, G. Przybylski, Barbara Balicka-Ślusarczyk, A. Jarzemska, Tomasz Wandtke, Ewelina Półgesek, Magda Igielska, Elevation of serum tumor markers in patients with interstitial lung disease, paper, 2011*
37) *Sungho Bea, Hyesung Lee, J. H. Kim, S. Jang, Hyunjin Son, J. Kwon, Ju-Young Shin, Adherence and Associated Factors of Treatment Regimen in Drug-Susceptible Tuberculosis Patients, paper, 2021*
38) *Elena Cojocaru, Tudor Cojocaru, Giulia-Mihaela Pinzariu, Ioana Vasiliu, I. Armașu, Cristian Cojocaru, Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment, paper, 2023*
39) *A. Jose, F. Mccormack, J. Elwing, Heart Rate Variability as a Novel Biomarker of Treatment Response in Pulmonary Arterial Hypertension, paper, 2022*
40) *Urvi J. Patel, J. Abernathy, B. Savani, O. Oluwole, S. Sengsayadeth, B. Dholaria, CAR T cell therapy in solid tumors: A review of current clinical trials, paper, 2021*
41) *Megan J Eberle, Aline B Thorkelsson, Lane J Liddle, Mohammed Almekhlafi, F. Colbourne, Longer Periods of Hypothermia Provide Greater Protection Against Focal Ischemia: A Systematic Review of Animal Studies Manipulating Treatment Duration., paper, 2023*
42) *Yuan Liu, Ziwen Tong, Jingru Shi, Ruichao Li, M. Upton, Zhiqiang Wang, Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria, paper, 2021*

43) Š. Laššán, T. Tesar, J. Tisoňová, M. Laššánová, Pharmacological approaches to pulmonary fibrosis following COVID-19, paper, 2023